Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients

Breast Cancer

Volumn 17, Issue 4, 2010, Pages 247-253

  Watanabe, Naoki ^a   Ootawa, Yasuyuki ^a   Kodama, Kikue ^a   Kaide, Akemi ^a   Ootsuka, Nobutoshi ^a   Matsuoka, Jyunji ^b  

^a CHUGOKU CENTRAL HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Aromatase inhibitor; Concurrent or sequential administration; Postmenopausal breast cancer; Primary systemic therapy

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NITRILES; PACLITAXEL; POSTMENOPAUSE; TREATMENT OUTCOME; TRIAZOLES; TUMOR BURDEN;

EID: 77958092387     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0144-6     Document Type: Article

References (21)

1. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 1:CAS:528:DyaK1cXlsFCgurg%3D 9704717
2. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 1:CAS:528:DyaK1MXht1Wmur4%3D 10080586
3. JY Pierga E Mouret V Dieras V Laurence P Beuzeboc T Dorval, et al. 2000 Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer Br J Cancer 83 1480 1487 1:STN:280:DC%2BD3M%2FmsFKisA%3D%3D 10.1054/bjoc.2000.1461 11076657
4. HD Bear S Anderson A Brown R Smith EP Mamounas B Fisher, et al. 2003 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 4165 4174 1:CAS:528:DC%2BD2cXpsVajtrg%3D 10.1200/JCO.2003.12.005 14559892 (Pubitemid 46606185)
5. M Colleoni G Viale D Zahrieh G Pruneri O Gentilini P Veronesi, et al. 2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 6622 6628 1:CAS:528:DC%2BD2cXot1Oiu7o%3D 10.1158/1078-0432.CCR-04- 0380 15475452 (Pubitemid 39346559)
6. ER Fisher J Wang J Bryant B Fisher E Mamounas N Wolmark 2002 Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 Cancer 95 681 695 10.1002/cncr.10741 12209710 (Pubitemid 34845919)
7. V Guarneri K Broglio SW Kau M Cristofanilli AU Buzdar V Valero, et al. 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 10.1200/JCO.2005.02.6914 16505422 (Pubitemid 46638799)
8. CK Osborne 1981 Combined chemo-hormonal therapy in breast cancer: a hypothesis Breast Cancer Res Treat 1 121 123 1:STN:280:DyaL3s%2FnsF2isg%3D%3D 10.1007/BF01805864 7348568
9. Albain K, Green S, Ravdin P (eds). Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol. 2002.
10. IE Smith M Dowsett SR Ebbs JM Dixon A Skene JU Blohmer, et al. 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108 5116 1:CAS:528:DC%2BD2MXpsFWmtLY%3D 10.1200/JCO.2005.04.005 15998903 (Pubitemid 46224019)
11. W Eiermann S Paepke J Appfelstaedt A Llombart-Cussac J Eremin J Vinholes, et al. 2001 Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 1527 1532 1:STN:280:DC%2BD38%2FptlGisw%3D%3D 10.1023/A:1013128213451 11822750 (Pubitemid 34065880)
12. R Kim K Tanabe M Emi Y Uchida A Osaki T Toge 2005 Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer Int J Oncol 26 1025 1031 1:CAS:528:DC%2BD2MXjtFelsbk%3D 15753998
13. Y Tabuchi J Matsuoka M Gunduz T Imada R Ono M Ito, et al. 2009 Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer Int J Oncol 34 313 319 1:CAS:528:DC%2BD1MXisVGjtbc%3D 19148464
14. M Dowsett J Cuzick A Howell I Jackson 2001 Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial Br J Cancer 85 317 324 1:CAS:528:DC%2BD3MXmslSgsbc%3D 10.1054/bjoc.2001.1925 11487258 (Pubitemid 32747695)
15. JM Dixon L Renshaw O Young J Murray EJ Macaskill M McHugh, et al. 2008 Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer J Clin Oncol 26 1671 1676 1:CAS:528:DC%2BD1cXltlWhsrk%3D 10.1200/JCO.2007.13.9279 18375896
16. JCOG. Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0). JCOG; 2007/3/8 [updated 2007/3/8; cited 2008]. Available from: http://www.jcog.jp/SHIRYOU/ctcae.htm.
17. C Pico M Martin C Jara A Barnadas A Pelegri A Balil, et al. 2004 Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study Ann Oncol 15 79 87 1:STN:280:DC%2BD3srps1Kmtg%3D%3D 10.1093/annonc/mdh016 14679124 (Pubitemid 38139607)
18. L Del Mastro B Dozin E Aitini T Catzeddu E Baldini A Contu, et al. 2008 Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group Ann Oncol 19 299 307 1:STN:280: DC%2BD1c%2Fotleisw%3D%3D 10.1093/annonc/mdm475 17947224 (Pubitemid 351201711)
19. M Yoshida O Abe J Uchino K Kikuchi R Abe K Enomoto, et al. 1997 Meta-Analysis of the Second Collaborative Study of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) in Patients with Stage II, Estrogen-Receptor-Positive Breast Cancer Breast Cancer 4 93 101 10.1007/BF02967062 11091583
20. T Morimoto M Ogawa K Orita K Sugimachi T Toge K Dohi, et al. 1996 Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan Eur J Cancer 32A 235 242 1:CAS:528:DyaK28Xitl2hsb0%3D 10.1016/0959-8049(95)00579-X 8664034
21. C Liedtke C Mazouni KR Hess F Andre A Tordai JA Mejia, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147 18250347